1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsCell and Gene Therapy (CGT) Access Model is sponsored by Mississippi Division of Medicaid (in partnership with CMS). This model focuses on Cell and Gene Therapies (CGTs) for sickle cell disease. Mississippi's participation began January 1, 2026.
Get alerted about grants like this
Get emailed when new opportunities from “Mississippi Division of Medicaid (in partnership with CMS)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Cell and Gene Therapy (CGT) Access Model - Mississippi Division of Medicaid Cell and Gene Therapy (CGT) Access Model - Mississippi Division of Medicaid MESA Portal for Providers   |   Cell and Gene Therapy (CGT) Access Model Mississippi Division of Medicaid > Cell and Gene Therapy (CGT) Access Model Centers for Medicare and Medicaid Services (CMS) Cell and Gene Therapy (CGT) Access Model Overview The Cell and Gene Therapy (CGT) Access Model is a multi-year model for states and manufacturers to test whether a CMS-led approach to developing and administering outcomes-based agreements for CGTs increases Medicaid members’ access to innovative treatments, improves their health outcomes, and reduces health care costs and burden to state Medicaid programs.
The initial focus of the model is on CGTs for sickle cell disease. The Mississippi Division of Medicaid is participating in the CGT Access Model beginning on January 1, 2026. More information about the model can be found here: https://www.
cms. gov/priorities/innovation/innovation-models/cgt . Billing Instructions for Providers Pursuant to State Plan Amendment MS 25-0006, the Mississippi Division of Medicaid will reimburse select drugs provided in an inpatient hospital setting separately from the APR-DRG payment.
A separate claim must be submitted to receive reimbursement for select drugs during the time of inpatient services. The list of select high-cost drugs carved out of inpatient DRG rates can be found here: https://medicaid. ms.gov/providers/fee-schedules-and-rates/ .
Per the requirements set by this model, provider billing instructions for cell and gene therapies for sickle cell disease are linked below. Select High Cost Drugs Billing Instructions for Providers V2 Prior Authorization Criteria Per the requirements set by this model, prior authorization criteria for each CGT for sickle cell disease are linked below.
Please submit the prior authorization request to Telligen if the member is enrolled in fee-for-service or to the member’s respective coordinated care organization. CGT Access Model Cooperative Agreement Funding As the gene therapy journey is complex, states had the opportunity to apply for funding to implement services that improve members’ ability to access these promising therapies.
Mississippi was one of eight applicants awarded Cooperative Agreement funding through this Model.
Funding will be used across calendar years 2026 to 2030: Create dedicated patient support roles to guide and support members throughout their gene therapy treatment journey Partner with a community-based organization to: o Expand, and not duplicate or replace, transportation and travel-related support, including lodging and meals, for members and their caregivers o Connect patients and caregivers in the Model to subsidized childcare from licensed providers o Develop and launch educational and awareness efforts for members, providers, and local communities about sickle cell disease, cell and gene therapies, and supportive services available Funded through the Cooperative Agreement, the Program Coordinator is a position that will focus on supporting members who will receive CGT for sickle cell disease through the CMS Cell and Gene Therapy Access Model.
Responsibilities of this role include, but are not limited to: Act as the primary liaison for the CGT Access Model Guide Model members through the full treatment journey Connect members to supportive resources The individual serving as the Program Coordinator is Amber Finley. For questions related to the CGT Access Model, please email Amber. Finley@medicaid.
ms.gov . Educational and Awareness Initiatives Please stay tuned for educational and awareness resources and initiatives. The Mississippi Division of Medicaid responsibly provides access to quality health coverage for vulnerable Mississippians.
Mississippi Division of Medicaid Jackson, Mississippi 39225 Notice of Non-Discrimination Mississippi's Official State website Centers for Medicare and Medicaid Services
According to the current listing, eligibility includes: Community-based organizations in Mississippi can partner with the Mississippi Division of Medicaid to provide supportive services. Confirm the full requirements in the official notice before applying.
Cell and Gene Therapy (CGT) Access Model is funded by Mississippi Division of Medicaid (in partnership with CMS). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Mississippi. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
CMS awarded the entire $50 billion Rural Health Transformation Program to all 50 states, with first-year checks averaging $200M per state and money starting to move October 1, 2026. The federal contest is over — but for rural hospitals, clinics, behavioral-health providers, and nonprofits, the real competition is just beginning inside each state's sub-grant process. Here is how the money splits, what it can fund, and how to position now.
Read articleCMS awarded all 50 states their first-year slice of the $50 billion Rural Health Transformation Program in December 2025 — from $147M in New Jersey to $281M in Texas. Now the money is moving downstream: New Jersey and New York have already launched subaward RFAs, and rural hospitals, clinics, community organizations, and tribal groups are the eligible applicants. Here is how the allocation formula worked, what the money can and cannot fund, and the strategy to win a state subaward.
Read articleCMS awarded all 50 states a slice of the $50 billion Rural Health Transformation Program on December 29, 2025 — first-year checks average $200M, ranging from $147M to $281M. The federal application is closed and you cannot apply to CMS. The money reaches hospitals, clinics, and nonprofits only as state subawards, and those competitions open through 2026. Here is how the formula worked, what the funds can and cannot buy, and how to position for a subaward before the money starts flowing.
Read article